IRIDEX Corporation (IRIX)
| Market Cap | 55.33M |
| Revenue (ttm) | 55.33M |
| Net Income (ttm) | -5.61M |
| Shares Out | 18.20M |
| EPS (ttm) | -0.34 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 16,665 |
| Open | 3.17 |
| Previous Close | 3.09 |
| Day's Range | 3.00 - 3.17 |
| 52-Week Range | 2.88 - 9.46 |
| Beta | 1.20 |
| Analysts | Buy |
| Price Target | 9.95 (+227.3%) |
| Earnings Date | May 12, 2022 |
About IRIX
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems tha...
Financial Performance
In 2021, IRIDEX's revenue was $53.90 million, an increase of 48.30% compared to the previous year's $36.35 million. Losses were -$5.23 million, -17.44% less than in 2020.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for IRIX stock is "Buy." The 12-month stock price forecast is 9.95, which is an increase of 227.30% from the latest price.
News
Iridex (IRIX) Reports Q1 Loss, Misses Revenue Estimates
Iridex (IRIX) delivered earnings and revenue surprises of 6.25% and 0.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Iridex Announces First Quarter 2022 Financial Results
Achieved Record First Quarter Revenue Achieved Record First Quarter Revenue
Iridex to Report First Quarter 2022 Financial Results on May 12, 2022
MOUNTAIN VIEW, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal di...
Iridex Announces the Appointment of Beverly Huss to its Board of Directors
MOUNTAIN VIEW, Calif., March 21, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal di...
Iridex (IRIX) Reports Q4 Loss, Tops Revenue Estimates
Iridex (IRIX) delivered earnings and revenue surprises of -36.36% and 0.51%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Iridex Announces Fourth Quarter and Full Year 2021 Financial Results
Exceeds Prior Guidance with Record Fourth Quarter Revenue and 48% Full Year Revenue Growth Exceeds Prior Guidance with Record Fourth Quarter Revenue and 48% Full Year Revenue Growth
Iridex to Present at the 34th Annual Roth Conference
MOUNTAIN VIEW, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal di...
Iridex to Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022
MOUNTAIN VIEW, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal dis...
Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2021
Exceeds Prior Guidance with Record Quarterly Revenue and nearly 50% Full Year Revenue Growth Exceeds Prior Guidance with Record Quarterly Revenue and nearly 50% Full Year Revenue Growth
Iridex Announces Third Quarter 2021 Financial Results
Achieved 51% Year-over-Year Revenue Growth and Raises 2021 Revenue Guidance Achieved 51% Year-over-Year Revenue Growth and Raises 2021 Revenue Guidance
Iridex (IRIX) Soars 7.3%: Is Further Upside Left in the Stock?
Iridex (IRIX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Retina and Glaucoma Experts Will Present Best Practices Using Iridex Technologies at a Consensus Panel and the AAO An...
An international expert consensus panel will discuss best practices in dosing and patient selection using MicroPulse TLT on November 6, 2021
Earnings Preview: Iridex (IRIX) Q3 Earnings Expected to Decline
Iridex (IRIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Iridex to Report Third Quarter 2021 Financial Results on November 11, 2021
MOUNTAIN VIEW, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal dis...
Iridex to Present at the Lytham Partners Fall 2021 Investor Conference
MOUNTAIN VIEW, Calif., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal di...
Is IRIDEX (IRIX) Stock a Solid Choice Right Now?
IRIDEX (IRIX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Iridex Stock Gains After Posting Highest Sales Since 2007
Iridex Corporation (NASDAQ: IRIX) reported Q2 revenue of $13.4 million, the highest since 2007, +116% Y/Y, beating the consensus of $11.61 million. Cyclo G6 product family generated sales of $3.6 millio...
Iridex (IRIX) Reports Q2 Loss, Tops Revenue Estimates
Iridex (IRIX) delivered earnings and revenue surprises of 43.75% and 15.65%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Iridex: Q2 Earnings Insights
Shares of Iridex (NASDAQ:IRIX) moved higher by 1.4% in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 145.00% over the past year to $0.09, which be...
Iridex to Present at the 2021 H.C. Wainwright Ophthalmology Virtual Conference
MOUNTAIN VIEW, Calif., Aug. 09, 2021 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal dis...
Will Iridex (IRIX) Report Negative Q2 Earnings? What You Should Know
Iridex (IRIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Iridex Announces First Quarter 2021 Financial Results
MOUNTAIN VIEW, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX) today reported financial results for the first quarter ended April 3, 2021.
Earnings Preview: Iridex (IRIX) Q1 Earnings Expected to Decline
Iridex (IRIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Iridex (IRIX) Beats on Q4 Earnings, Revenues Increase Y/Y
Iridex's (IRIX) fourth-quarter 2020 results benefit from strong product line-up and expanding market position.